Stryker Q2 FY2026: sales up 9.4%, adjusted EPS $3.69, guidance narrowed
Stryker reported $6.589 billion of revenue for Q2 FY2026, up 9.4%, and adjusted EPS of $3.69 against a $3.5233 consensus, with both segments growing near 9%. Read the beat as real, and the narrowed guidance as a sign management sees the cyber recovery holding. But the reported 68.3% gross margin carries a $158 million reversal of 2025 tariffs inside it, so the durable margin is nearer 66.0%.
1 · Expected vs. Actual
Free preview belowGAAP EPS was $3.30, up 44.1%, while adjusted EPS was $3.69, up 17.9% and ahead of the $3.5233 consensus. The adjusted number strips out items such as $175 million of purchased-intangible amortization and $95 million of structural optimization charges. Be aware that $0.34 of the reported EPS and $158 million of gross profit come from reversing 2025 tariffs.
Revenue of $6.589 billion rose 9.4% as reported and 9.0% organically versus $6.022 billion a year ago. MedSurg and Neurotechnology grew 9.7% and Orthopaedics 9.1%, so the growth is broad rather than one segment carrying the quarter. The press release credits unit volume for the organic gain, with pricing roughly flat.
Log in to read 5 analyses a week for free
Create a free account to read 5 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.